Ladiratuzumab vedotin
Product Specifications
CAS Number
1629760-29-7
Target
Antibody-Drug Conjugates (ADCs)
Related Pathways
Antibody-drug Conjugate/ADC Related
Bioactivity
Ladiratuzumab vedotin (SGN-LIV1A) is an ADC (IC 50: 5.6 nM for LIV-1) that targets LIV-1. This compound is composed of a humanized IgG1 monoclonal antibody, linked to MMAE via a protease-cleavable linker. It induces immunogenic cell death (ICD), which triggers an immune response. Ladiratuzumab vedotin is utilized in breast cancer research [1] [2] [3] [4].
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
032193-ML405 100 µL
ATG4A (ATG4A, APG4A, AUTL2, Cysteine protease ATG4A, AUT-like 2 cysteine endopeptidase, Autophagin-2, Autophagy-related cysteine endopeptidase 2, Autophagy-related protein 4 homolog A) (MaxLight 405) discontinued
Ask
View Details 
